| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC3751 |
| Trial ID | NCT06249438 |
| Disease | Systemic Lupus Erythematosus | Immune-Mediated Necrotizing Myopathy | Neuromyelitis Optica Spectrum Disorder |
| Altered gene | CD20|BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | C-CAR168 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | An Exploratory Clinical Study of Anti-B-cell Maturation Antigen(BCMA)/Cluster of Differentiation Antigen 20(CD20) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy |
| Year | 2024 |
| Country | China |
| Company sponsor | RenJi Hospital |
| Other ID(s) | 1141-043(CAR-AID) |
| Cohort 1 | |||||||||
|
|||||||||